ACC017 vs Cabotegravir (Apretude)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV integrase · full HIV pipeline
ACC017
Developed by Jiangsu Aidea Pharmaceutical Group
NCT06719310 · Phase 1/2 · completed
The first stage of this study randomly assigned patients to ACC017 or placebo under double-blind conditions, a strong design, and its primary endpoints include the proportion of patients reaching an undetectable HIV-1 viral load, a disease-defining measure for HIV therapy. However, results have not yet been posted, so whether the drug met that goal is not yet known.
Next expected readout: June 2027 · NCT07711210 (registry estimate)
Reported efficacy
Report the incidence, severity and seriousness of adverse events, and the relationship between drug and AE (Day 1- Day 11); HIV-1 RNA viral load change from baseline (Day 11); Proportion of patients with HIV-1 RNA viral load <50 copies/mL (Day 29); Pharmacokinetics parameter: Cτ,ss (Day 10, Day 29); Pharmacokinetics parameter: Cmin,ss (Day 10); Pharmacokinetics parameter: Cmax,ss (Day 10); Pharmacokinetics parameter: AUC0-τ,ss (Day 1- Day 10); Pharmacokinetics parameter: Tmax,ss (Day 1-Day 10); Pharmacokinetics parameter: MRT0-τ,ss (Day 1-Day 10): The mean decrease in the groups ranged from 1.44 to 2.34 log 10 copies/mL and none of the participants experienced viral breakthrough. A total of 86.11% of the participants had HIV-RNA of less than 50 copies/mL at day 29. (not_applicable)
Result source: NCT06719310
Cabotegravir (Apretude)
Marketed by GlaxoSmithKline
NCT02720094 · Phase 2/3 · completed
The trial randomized 4,570 participants to cabotegravir or active-controlled TDF/FTC treatment and used quadruple blinding of participants, clinicians, investigators, and outcome assessors. Its hard clinical primary efficacy endpoint—documented incident HIV infection—was met, with 13 versus 39 infections and a hazard ratio of 0.340 (95% CI 0.18–0.62; p=0.0005).
Next expected readout: August 2028 · NCT06474364 (registry estimate)
Reported efficacy
Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.); Number of Participants Experiencing Grade 2 or Higher Clinical and Laboratory Adverse Events (Treatment emergent AE* measured with onset date through participant's last study visit, or the date of DSMB decision to unblind all participants, whichever is earliest. Assessed at each visit (injections visits q 8 weeks and safety visits q 8 weeks).): Number of Participants With Documented Incident HIV Infections During Steps 1 and 2 (HIV tests at enrollment, weeks 2, 4, 5, every injection visit (every 8 weeks) and every safety visit (2 weeks after each injection visit). Analyzed through week 153 or the date of DSMB decision to unblind all participants, whichever is earliest.): Cabotegravir 13/2280 vs TDF/FTC 39/2281 (met)
Result source: NCT02720094
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | ACC017 | Cabotegravir (Apretude) |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Trial running · NCT07711223 | —Trial running · NCT06133686 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Trial running · NCT07711223 | —Trial running · NCT06133686 |
| CD4 count, change (week 48) | —Trial running · NCT07711223 | —Trial running · NCT06133686 |
HIV-1 RNA below 50 copies/mL (week 48)
- ACC017
- —Trial running · NCT07711223
- Cabotegravir (Apretude)
- —Trial running · NCT06133686
HIV-1 RNA 50 copies/mL or more (week 48)
- ACC017
- —Trial running · NCT07711223
- Cabotegravir (Apretude)
- —Trial running · NCT06133686
CD4 count, change (week 48)
- ACC017
- —Trial running · NCT07711223
- Cabotegravir (Apretude)
- —Trial running · NCT06133686
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: ACC017's landscape · Cabotegravir (Apretude)'s landscape